Top Markets
#1 MowCat MowCat +49.46%
#2 Velvet Velvet +22.61%
#3 Fake World Assets Fake World Assets +18.71%
#4 Block Street Block Street +18.17%
#5 Perle Perle +17.18%
#6 Quack AI Quack AI +15.64%
#7 Bermuda Shorts Bermuda Shorts +14.89%
#8 Derive Derive +14.15%
#9 Palladium Network Palladium Network +13.89%
#10 DUSK Network DUSK Network +13.03%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Integrated BioPharma, Inc. Integrated BioPharma, Inc.

Integrated BioPharma, Inc.

INBP
Rank in Stocks #34626
Integrated BioPharma, Inc., together with its subsidiaries, engages in the... Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Share Price
$0.16795
Last synced: 2026-08-14
Market Cap
$5.22M
Change (1 day)
4.97%
Change (1 year)
-37.80%
Country
US
Trade Integrated BioPharma, Inc. (INBP)

Category

Healthcare
P/E ratio for Integrated BioPharma, Inc. (INBP)
P/E ratio as of 2026 TTM: 0
According to Integrated BioPharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Integrated BioPharma, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 24.32 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.13 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.